Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
July 2, 4:20 PM
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential of 5-MeO-DMT for the treatment of psychiatric and neurological disorders, is now listing its stock on the Nasdaq under the symbol “GHRS.”
June 30, 6:14 PM
Institutional analysts are taking a liking to the industry of medicinal psychedelics. This week, investment bank Maxim Group initiated coverage of companies in the psychedelics space, giving a bullish Buy rating to all 10.
Psyched: Atai’s $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers
June 14, 9:18 AM
Atai Launches $214 Million Nasdaq IPO Offering Psychedelics biotech platform Atai life Sciences has announced an initial public offering of approximately 14 million of its common shares, ahead of the company’s expected Nasdaq listing.
Psyched: Nasdaq Gets Its Third Psychedelics Company, Mynd Goes Public, Delic Buys New Research Facility
May 28, 3:45 PM
The Nasdaq welcomed its third psychedelics company this week, with the acquisition of MagicMed Industries by Enveric Biosciences (NASDAQ:
May 26, 4:56 PM
Hifyre President Matthew Hollingshead Named Fire & Flower CINO Fire & Flower Holdings Corp (TSX: FAF) (OTCQX: FFLWF) said Friday it had named Matthew Hollingshead, president of its wholly-owned indirect subsidiary, Hifyre Inc., its new chief innovation officer.
May 11, 1:32 PM
The psychedelics industry has started to gain serious traction and is attracting lots of attention these days. However, what many people may not know is that the sector has been up and running for decades, with various psychedelic substances already being used for medical treatment.